<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/10/1074g" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/10/1074g/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/10/1074g/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1074g"><akn:num>1074g</akn:num><akn:heading>Pharmacy benefits program</akn:heading><akn:content><akn:p>§ 1074g. Pharmacy benefits program(a) Pharmacy Benefits.—(1) The Secretary of Defense, after consulting with the other administering Secretaries, shall establish an effective, efficient, integrated pharmacy benefits program under this chapter (hereinafter in this section referred to as the “pharmacy benefits program”).

(2)(A) The pharmacy benefits program shall include a uniform formulary of pharmaceutical agents, which shall assure the availability of pharmaceutical agents in the complete range of therapeutic classes. The selection for inclusion on the uniform formulary of particular pharmaceutical agents in each therapeutic class shall be based on the relative clinical and cost effectiveness of the agents in such class. With respect to members of the uniformed services, such uniform formulary shall include pharmaceutical agents on the joint uniform formulary established under section 715 of the National Defense Authorization Act for Fiscal Year 2016.

(B) In considering the relative clinical effectiveness of agents under subparagraph (A), the Secretary shall presume inclusion in a therapeutic class of a pharmaceutical agent, unless the Pharmacy and Therapeutics Committee established under subsection (b) finds that a pharmaceutical agent does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome over the other drugs included on the uniform formulary.

(C) In considering the relative cost effectiveness of agents under subparagraph (A), the Secretary shall rely on the evaluation by the Pharmacy and Therapeutics Committee of the costs of agents in a therapeutic class in relation to the safety, effectiveness, and clinical outcomes of such agents.

(D) The Secretary shall establish procedures for the selection of particular pharmaceutical agents for the uniform formulary. Such procedures shall be established so as best to accomplish, in the judgment of the Secretary, the objectives set forth in paragr</akn:p></akn:content><akn:subsection eId="subsec_1074g_a"><akn:num>(a)</akn:num><akn:heading>Pharmacy Benefits.—</akn:heading><akn:content><akn:p>(a)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_b"><akn:num>(b)</akn:num><akn:heading>Establishment of Committee.—</akn:heading><akn:content><akn:p>(b)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_c"><akn:num>(c)</akn:num><akn:heading>Advisory Panel.—</akn:heading><akn:content><akn:p>(c)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_d"><akn:num>(d)</akn:num><akn:heading>Procedures.—</akn:heading><akn:content><akn:p>(d)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_e"><akn:num>(e)</akn:num><akn:heading>Pharmacy Data Transaction Service.—</akn:heading><akn:content><akn:p>(e) The Secretary of Defense shall implement the use of the Pharmacy Data Transaction Service in all fixed facilities of the uniformed services under the jurisdiction of the Secretary, in the TRICARE retail pharmacy program, and in the national mail-order pharmacy program.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_f"><akn:num>(f)</akn:num><akn:heading>Procurement of Pharmaceuticals by TRICARE Retail Pharmacy Program.—</akn:heading><akn:content><akn:p>(f) With respect to any prescription filled after January 28, 2008, the TRICARE retail pharmacy program shall be treated as an element of the Department of Defense for purposes of the procurement of drugs by Federal agencies under section 8126 of title 38 to the extent necessary to ensure that pharmaceuticals paid for by the Department of Defense that are provided by pharmacies under the program to eligible covered beneficiaries under this section are subject to the pricing standards in such section 8126.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_g"><akn:num>(g)</akn:num><akn:heading>Sharing of Information With State Prescription Drug Monitoring Programs.—</akn:heading><akn:content><akn:p>(g)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_h"><akn:num>(h)</akn:num><akn:heading>Labeling.—</akn:heading><akn:content><akn:p>(h) The Secretary of Defense shall ensure that drugs made available through the facilities of the armed forces under the jurisdiction of the Secretary include labels and other labeling that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_i"><akn:num>(i)</akn:num><akn:heading>Definitions.—</akn:heading><akn:content><akn:p>(i) In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1074g_j"><akn:num>(j)</akn:num><akn:heading>Regulations.—</akn:heading><akn:content><akn:p>(j) The Secretary of Defense shall, after consultation with the other administering Secretaries, prescribe regulations to carry out this section.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>